![Alan Colowick](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Alan Colowick currently works as a Director at Solve Therapeutics, Inc.
Actieve functies van Alan Colowick
Bedrijven | Functie | Begin |
---|---|---|
Solve Therapeutics, Inc.
![]() Solve Therapeutics, Inc. BiotechnologyHealth Technology Solve Therapeutics, Inc. is an oncology-focused biopharmaceutical company that develops novel antibody-based therapies targeting tumor-specific antigens. The company is based in Belmont, CA, and has subsidiaries in the United States. The company's formation has reunited members of the former VelosBio Inc. team, a highly experienced group with a proven ability to rapidly advance innovative therapeutics that address unmet medical needs in the treatment of cancer. Solvetx has been actively pursuing discovery and development efforts at its state-of-the-art laboratory facilities. The company has licensed or generated targeting antibodies and nanobodies with ideal characteristics to serve as the backbones for antibody-based therapeutics and has rights to technology supporting the development of diagnostic and therapeutic antibody-radionuclide conjugates (ARCs). Solvetx is supported by a syndicate of sophisticated healthcare investors, including Ayurmaya Capital Management Fund (an affiliate of Matrix Capital Management), Decheng Capital, General, and Surveyor Capital (a Citadel company). The company was founded by David M. Johnson and has been led by him as the CEO since incorporation. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Solve Therapeutics, Inc.
![]() Solve Therapeutics, Inc. BiotechnologyHealth Technology Solve Therapeutics, Inc. is an oncology-focused biopharmaceutical company that develops novel antibody-based therapies targeting tumor-specific antigens. The company is based in Belmont, CA, and has subsidiaries in the United States. The company's formation has reunited members of the former VelosBio Inc. team, a highly experienced group with a proven ability to rapidly advance innovative therapeutics that address unmet medical needs in the treatment of cancer. Solvetx has been actively pursuing discovery and development efforts at its state-of-the-art laboratory facilities. The company has licensed or generated targeting antibodies and nanobodies with ideal characteristics to serve as the backbones for antibody-based therapeutics and has rights to technology supporting the development of diagnostic and therapeutic antibody-radionuclide conjugates (ARCs). Solvetx is supported by a syndicate of sophisticated healthcare investors, including Ayurmaya Capital Management Fund (an affiliate of Matrix Capital Management), Decheng Capital, General, and Surveyor Capital (a Citadel company). The company was founded by David M. Johnson and has been led by him as the CEO since incorporation. | Health Technology |